Level Chart

Basic Info

Regeneron Pharmaceuticals (REGN) - Net Product Sales Revenue is at a current level of 1.588B, down from 1.631B last quarter and down from 1.946B one year ago. This is a change of -2.65% from last quarter and -18.43% from one year ago.

Region United States
Source Fiscal.ai

Data provided via Fiscal.ai

Stats

Last Value 1.588B
Latest Period Sep 2025
Last Updated Dec 18 2025, 15:09 EST
Next Release Jan 30 2026, 08:30 EST (E)
Average Growth Rate 25.59%
Value from Last Quarter 1.631B
Change from Last Quarter -2.65%
Value from 1 Year Ago 1.946B
Change from 1 Year Ago -18.43%
Frequency Quarterly
Unit USD
Adjustment N/A
Download Source File Upgrade

Historical Data

View and export this data back to 2019. Upgrade now.
Date Value
September 30, 2025 1.588B
June 30, 2025 1.631B
March 31, 2025 1.416B
December 31, 2024 2.003B
September 30, 2024 1.946B
June 30, 2024 1.919B
March 31, 2024 1.761B
December 31, 2023 1.852B
September 30, 2023 1.786B
June 30, 2023 1.772B
March 31, 2023 1.668B
December 31, 2022 1.699B
Date Value
September 30, 2022 1.801B
June 30, 2022 1.754B
March 31, 2022 1.639B
December 31, 2021 3.975B
September 30, 2021 2.280B
June 30, 2021 4.138B
March 31, 2021 1.724B
December 31, 2020 1.622B
September 30, 2020 1.482B
June 30, 2020 1.227B
March 31, 2020 1.237B
December 31, 2019 1.286B

Basic Info

Regeneron Pharmaceuticals (REGN) - Net Product Sales Revenue is at a current level of 1.588B, down from 1.631B last quarter and down from 1.946B one year ago. This is a change of -2.65% from last quarter and -18.43% from one year ago.

Region United States
Source Fiscal.ai

Data provided via Fiscal.ai

Stats

Last Value 1.588B
Latest Period Sep 2025
Last Updated Dec 18 2025, 15:09 EST
Next Release Jan 30 2026, 08:30 EST (E)
Average Growth Rate 25.59%
Value from Last Quarter 1.631B
Change from Last Quarter -2.65%
Value from 1 Year Ago 1.946B
Change from 1 Year Ago -18.43%
Frequency Quarterly
Unit USD
Adjustment N/A
Download Source File Upgrade

Related Securities

Symbol Name Change %
REGN Regeneron Pharmaceuticals, Inc. -0.27%